ArQule and Kyowa Hakko Kogya Sign Exclusive Licence Agreement for Cancer Drug in Asia
By Business Review Editor
Pharma Deals Review: Vol 2007 Issue 84 (Table of Contents)
Published: 7 Jun-2007
DOI: 10.3833/pdr.v2007.i84.333 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
ArQule and Kyowa Hakko Kogya entered into exclusive license agreement to develop and commercialize ArQule’s ARQ 197 for treating cancer...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS